Sex and Gender Differences in the Effects of Novel Psychoactive Substances.
Liana Fattore, Matteo Marti, Rafaela Mostallino, Maria Paola Castelli
Brain Sciences September 3, 2020 DOI: 10.3390/brainsci10090606 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Nps Cannabinoids Cathinones New synthetic drugs Opioids Phenethylamines Sex/gender differences |
| Citations | 63 |
| Key findings | Sex and gender differences in the effects of new psychoactive substances remain largely unstudied and poorly understood. |
Abstract
Sex and gender deeply affect the subjective effects and pharmaco-toxicological responses to drugs. Men are more likely than women to use almost all types of illicit drugs and to present to emergency departments for serious or fatal intoxications. However, women are just as likely as men to develop substance use disorders, and may be more susceptible to craving and relapse. Clinical and preclinical studies have shown important differences between males and females after administration of "classic" drugs of abuse (e.g., Δ9-tetrahydrocannabinol (THC), morphine, cocaine). This scenario has become enormously complicated in the last decade with the overbearing appearance of the new psychoactive substances (NPS) that have emerged as alternatives to regulated drugs. To date, more than 900 NPS have been identified, and can be catalogued in different pharmacological categories including synthetic cannabinoids, synthetic stimulants (cathinones and amphetamine-like), hallucinogenic phenethylamines, synthetic opioids (fentanyls and non-fentanyls), new benzodiazepines and dissociative anesthetics (i.e., methoxetamine and phencyclidine-derivatives). This work collects the little knowledge reached so far on the effects of NPS in male and female animal and human subjects, highlighting how much sex and gender differences in the effects of NPS has yet to be studied and understood.
Citations in the library
Cited by 15
- Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL/6J mice. Neuroscience Letters September 25, 2022
- Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics. Molecular Psychiatry September 1, 2023
- Therapeutic potential of psychedelics: History, advancements, and unexplored frontiers. Progress in Neuro-Psychopharmacology and Biological Psychiatry April 20, 2024
- Pharmaco-toxicological effects of the novel tryptamine hallucinogen 5-MeO-MiPT on motor, sensorimotor, physiological, and cardiorespiratory parameters in mice-from a human poisoning case to the preclinical evidence. Psychopharmacology March 1, 2024
- The rising use of cognitive enhancement drugs and predictors of use during COVID-19: findings from a cross-sectional survey of students and university staff in the UK. Frontiers in Psychology 2024
and 10 more in the library
Cites 34
- Beyond THC: The New Generation of Cannabinoid Designer Drugs Frontiers in Behavioral Neuroscience 2011
- Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants Frontiers in Neuroscience April 19, 2016
- Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT) PLoS One October 24, 2012
- Correlates of new psychoactive substance use among a self-selected sample of nightclub attendees in the United States. American Journal on Addictions August 1, 2016
- Hallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats Neurotoxicity Research April 15, 2019
and 29 more in the library